| Name | Leukemia (A:m6A) |
| Description | FTO highly expressed in AML t(11q23)/MLL rearrangements, t(15;17)/PML-RARA, FLT3-ITD and/or NPM1 mutations. FTO enhances leukemic oncogene-mediated cell transformation and leukemogenesis, and inhibits all-trans-retinoic acid (ATRA)-induced AML cell differentiation, through regulating expression of targets such as ASB2 and RARA by reducing m6A levels in these mRNA transcripts. |
| Related RNA reaction | A:m6A |
| Found in RNA | mRNA |
| Modified Transcript | ASB2 and RARA |
| Mapping Technology | MeRIP-seq |
| Quantification techniques | m6A quantification, Gene-Specific m6A qPCR |
| Acronym | Full name | Enzyme Role | Organism | Comment |
|---|---|---|---|---|
| FTO | Alpha-ketoglutarate-dependent dioxygenase FTO | oncogene | Homo sapiens |
| ID | Title | Authors | Journal | Details | ||
|---|---|---|---|---|---|---|
| 1064 | FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-Methyladenosine RNADemethylase. | Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, Huang H, Nachtergaele S, Dong L, Hu C, Qin X, Tang L, Wang Y, Hong GM, Huang H, Wang X, Chen P, Gurbuxani S, Arnovitz S, Li Y, Li S, Strong J, Neilly MB, Larson RA, Jiang X, Zhang P, Jin J, He C, Chen J | Cancer Cell | [details] | 28017614 | 10.1016/j.ccell.2016.11.017 |